Sickled beta globin antibodies
US-11535681-B2 · Dec 27, 2022 · US
against blood group antigens
against blood group antigens · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K16/34 |
| Official title | against blood group antigens |
| Display label | against blood group antigens |
| Total patents | 82 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 12 |
| 2020 | 8 |
| 2021 | 10 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 9 |
| 2025 | 7 |
| 2026 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Anti-c5 antibody combinations and uses thereof
US-2022275107-A1 · Sep 1, 2022 · US
Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US-11389523-B2 · Jul 19, 2022 · US
Ultra-stable protein ionic liquids
US-11382976-B1 · Jul 12, 2022 · US
Anti-C5 antibody combinations and uses thereof
US-11365265-B2 · Jun 21, 2022 · US
Ultrastable antibody ionic liquids
US-11338037-B1 · May 24, 2022 · US
Ultra-stable protein ionic liquids
US-11274163-B1 · Mar 15, 2022 · US
Hla binding vaccine moieties and uses thereof
US-2021403572-A1 · Dec 30, 2021 · US
Broadly neutralizing anti-human cytomegalovirus (HCMV) antibodies and methods of use thereof
US-11185582-B2 · Nov 30, 2021 · US
Compositions and methods for increasing protein half-life in a serum
US-11168146-B2 · Nov 9, 2021 · US
Methods and compositions for drug delivery
US-2021299272-A1 · Sep 30, 2021 · US
Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
US-2021292433-A1 · Sep 23, 2021 · US
Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
US-2021253676-A1 · Aug 19, 2021 · US
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
US-11046782-B2 · Jun 29, 2021 · US
Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies
US-2021047430-A1 · Feb 18, 2021 · US
RNA containing composition for treatment of tumor diseases
US-10918740-B2 · Feb 16, 2021 · US
Proteins Comprising Kallikrein Related Peptidase 2 Antigen Binding Domains And Their Uses
US-2021040210-A1 · Feb 11, 2021 · US
RNA containing composition for treatment of tumor diseases
US-10869935-B2 · Dec 22, 2020 · US
Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
US-10870692-B2 · Dec 22, 2020 · US
Sickled beta globin antibodies
US-2020347150-A1 · Nov 5, 2020 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K16/34?
- CPC C07K16/34 is the Cooperative Patent Classification code for “against blood group antigens.”
- How many patents are filed under CPC C07K16/34 (against blood group antigens)?
- Our database includes 82 publications tagged with this CPC code.
- Is patent activity under CPC C07K16/34 growing?
- Publication counts under this code: 9 in 2024 vs 7 in 2025 (latest complete years).